<DOC>
	<DOCNO>NCT00470015</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Aldesleukin may stimulate white blood cell kill tumor cell . Giving vaccine different dos GM-CSF mixed incomplete Freund 's adjuvant , without aldesleukin , may kill tumor cell . PURPOSE : This phase I trial study side effect well give vaccine therapy together GM-CSF , without low-dose aldesleukin , work treat patient stage II , stage III , stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF With Without Low-Dose Aldesleukin Treating Patients With Stage II , Stage III , Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity profile peptide vaccine comprise MART-1 antigen , gp100 antigen , survivin antigen combination sargramostim ( GM-CSF ) emulsify incomplete Freund 's adjuvant ( IFA ) without low-dose aldesleukin patient stage II-IV melanoma . - Determine immunologic effect two different dos GM-CSF coemulsified melanoma peptide IFA patient . - Determine immunological effect low-dose aldesleukin therapy administer peptide immunization patient . - Collect preliminary data impact vaccine clinical outcome patient . OUTLINE : This pilot study . Patients stratify accord disease stage ( II v III IV ) . Patients sequentially enrol 1 4 different dose schedule . - Dose schedule 1 : Patients receive gp100 antigen , MART-1 antigen , survivin antigen , sargramostim ( GM-CSF ) emulsify incomplete Freund 's adjuvant ( peptide vaccine ) subcutaneously ( SC ) day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Dose schedule 2 : Patients receive peptide vaccine group 1 . Patients also receive low-dose aldesleukin SC twice daily day 7-20 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Dose schedule 3 : Patients receive peptide vaccine group 1 except high dose GM-CSF . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Dose schedule 4 : Patients receive peptide vaccine group 1 except high dose GM-CSF . Patients also receive low-dose aldesleukin SC twice daily day 7-20 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Cohorts 5 patient receive treatment subsequent dose schedule maximum tolerate dose schedule ( MTDS ) determine . The MTDS define dose schedule precede 2 5 patient experience dose-limiting toxicity within first course . After completion study therapy , patient follow every 3 month 2 year . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma Stage IIIV disease Completely resect disease No known standard therapy potentially curative proven capable extend life expectancy exist HLAA2 positive PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,500/mm³ Hemoglobin &gt; 10 g/dL Platelet count ≥ 50,000/mm³ AST ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled current infection No known allergy vaccine immunoadjuvant components No know immune deficiency PRIOR CONCURRENT THERAPY : No chemotherapy within past 4 week recover No biologic therapy within past 4 week No radiation therapy within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>